MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Coverage is limited to plasma-based NGS (liquid biopsy) testing such as Guardant360 for patients with recurrent/relapsed/refractory/metastatic/advanced non–CNS solid tumors when tissue CGP is infeasible or, for NSCLC, tissue CGP shows no actionable mutations. Coverage requires no prior Guardant360 test for the same genetic content (unless there is documented cancer evolution warranting different-content retesting), the patient is untreated or not responding and intends further therapy, and the proposed treatment is FDA- or NCCN-supported based on biomarkers tested by the assay; negative or insufficient ctDNA should prompt consideration of tissue genotyping.

"Patient has a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that did not originate from the central nervous system."

Sign up to see full coverage criteria, indications, and limitations.